Research and Practice in Thrombosis and Haemostasis

Papers
(The H4-Index of Research and Practice in Thrombosis and Haemostasis is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Navigating the inevitable: artificial intelligence and the future of scientific communication88
Reevaluating thromboprophylaxis in COVID-19 outpatients: the case for a targeted, risk-based approach68
Intraindividual variability of von Willebrand factor and the need for repeated testing68
Promise and pitfalls of viscoelastic testing for assessing blood hemostasis in ultraendurance sports59
Contemporary trends in maternal outcomes during delivery hospitalizations among pregnancies complicated by von Willebrand disease—a cross-sectional analysis54
Acquired von Willebrand syndrome in children51
Thrombophilia and outcomes of venous thromboembolism in older patients44
140 Impact of Amiodarone Exposure on Apixaban Pharmacokinetics in Hospitalized Patients42
128 Evaluation of Heparin-Induced Thrombocytopenia Testing to Improve Anticoagulation Stewardship in an Acute Care Setting41
141 Heparin Management - The Ultimate Goldilocks Dilemma: A Quality Improvement Project40
84 Rural Improvements in Venous Thrombosis Treatment in Oklahoma: The RIVETT-OK Initiative39
Real-world andexanet alfa utilization and the association between delay in administration due to hospital transfer and all-cause inpatient mortality38
Performance of risk scores in predicting major bleeding in left ventricular assist device recipients: a comparative external validation37
Rare inherited coagulation disorders: no longer orphan and neglected36
How to use and report data on D‐dimer testing in the COVID‐19 era?34
PB0815 Involvement of the Nuclear Protein, TC2N, in Regulating VWF Levels in Endothelial Cells33
PB1117 Congenital Thrombotic Thrombocytopenic Purpura: Identification of Two Heterozygous Mutations in Splice Sites through NGS Sequencing32
OC 71.4 Management Patterns of Antithrombotics and Outcomes in Patients with Hematological Malignancy and Thrombocytopenia: A Prospective Registry (Matter Study)29
PB1385 Developing a Stem Cell-Based Model for Glanzmann Thrombasthenia to Explore VWF-GPIb Axis during Megakaryopoeisis29
OC 61.3 CS585 is a Novel and Highly Selective IP Receptor Agonist for Prevention of Thrombosis29
PB0046 Increased Platelet Activation Demonstrated by Elevated CD36 and P-Selectin Expression in 1-year Post Recovered COVID-19 Patients28
OC 42.5 Hemorrhagic Risk of Caplacizumab in the Treatment of Thrombotic Thrombocytopenic Purpura a Pharmacovigilance Study from 2020–2022 FAERS Database28
OC 03.2 Characterization of Peripheral Monocyte Subsets in a Prospective Cohort of Patients with Acute Stroke Suspicion: Results of BOOST Study28
PB0957 The Application of Existing Risk Assessment Models (RAMs) to Predict the Occurrence of Venous Thromboembolic Events among Patients with Classic Hodgkin's Lymphoma27
OC 53.5 Clinical Outcomes in Patients with Acute Pulmonary Embolism Undergoing Ultrasound-Assisted Catheter-Directed Thrombolysis27
PB0186 Results from BeneGene-1 Study: Prospective Collection of Bleeding Rate in Hemophilia B Patients Prior to Phase 3 Study (BeneGene-2) of Fidanacogene Elaparvovec25
PB0074 Hyper-Immunoglobulin-CovImmuneTM, Provides a Broader Coverage Against Diverse SARS-CoV-2 Variants Relevant to the COVID-19 Pandemic25
0.2632851600647